To Evaluate the Anti Inflammatory Effect of Metformin on C Reactive Protein in Newly Diagnosed Type 2 Diabetes Mellitus Patients: A Open Label Prospective Study Conducted in a Tertiary Care Hospital for 6 Months Period

Aim: To evalaute the pleiotropic effects of metfromin by measuring the Hs-CRP in newly diagnosed type 2 diabetes mellitus patients.

Materials and Method: A total of 70 patients were enrolled in the study, and out of that 50 patients who fulfilled the eligibility criteria were included in the study. And after randomization and obtaining the informed consent,50 patients were subjected to the trial drug-tablet Metformin 500mg twice daily for a period of 6 months and the patients were advised to follow at 3 and 6 months and hs-crp levels were measured at baseline and followup and patients were monitored for adverse drug events.

Results: hs-CRP baseline value expressed as Mean±SD was 3.4±1.16 mg/L . After 3 months of metformin therapy, hs-CRP reduced to 2.93±0.9 mg/L. After 6 months of metformin therapy, hs-CRP effectively reduced to 1.7±0.81 mg/L. hs-CRP levels were lowered after 6 months of treatment. Treatment with Metformin showed effective reduction in hs-CRP values comparatively between hs-CRP baseline values and hs-CRP values at sixth month were significant (P<0.05).

Conclusion: To conclude with the above findings shows that there was significant reduction in hs-CRP after six of therapy with metformin and hence proving its pleiotropic effects and hence apart from it’s a antidiabetic agent it proves its beneficial cardioprotective role in patients with newly diagnosed type 2 diabetes mellitus patients.